{
    "title": "Benefits of Novartis psoriasis drug outweighs risk: FDA staff",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2795556/Benefits-Novartis-psoriasis-drug-outweighs-risk-FDA-staff.html",
    "date": "2014-10-16",
    "keywords": [
        "drug",
        "psoriasis",
        "staff",
        "october",
        "biologic",
        "class",
        "il17",
        "plaquepsoriasis",
        "skin",
        "review",
        "panel",
        "study",
        "risk",
        "gmt",
        "email",
        "oct",
        "novartis",
        "type",
        "food",
        "administration",
        "saidthe",
        "secukinumab",
        "part",
        "success",
        "form",
        "conditiona",
        "laboratorysecukinumab",
        "ain457",
        "forerunner",
        "kind",
        "therapy",
        "protein",
        "interleukin17",
        "role",
        "inflammatory",
        "conditionsthe",
        "website",
        "fda",
        "autoimmune",
        "disorder",
        "etiology",
        "cell",
        "growth",
        "manifesting",
        "scaly",
        "worldwidea",
        "headtohead",
        "blockbuster",
        "enbrel",
        "superiority",
        "patientsthe",
        "recommendation",
        "data",
        "grover",
        "bangalore",
        "editing",
        "savio",
        "dsouza"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}